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CRISPR-Cas genome-editing nucleases hold substantial promise for developing human therapeutic applications 1-6 but identifying unwanted off-target mutations is important for clinical translation 7 . A well-validated method that can reliably identify off-targets in vivo has not been described to date, which means it is currently unclear whether and how frequently these mutations occur. Here we describe 'verification of in vivo off-targets' (VIVO), a highly sensitive strategy that can robustly identify the genome-wide offtarget effects of CRISPR-Cas nucleases in vivo. We use VIVO and a guide RNA deliberately designed to be promiscuous to show that CRISPR-Cas nucleases can induce substantial off-target mutations in mouse livers in vivo. More importantly, we also use VIVO to show that appropriately designed guide RNAs can direct efficient in vivo editing in mouse livers with no detectable off-target mutations. VIVO provides a general strategy for defining and quantifying the off-target effects of gene-editing nucleases in whole organisms, thereby providing a blueprint to foster the development of therapeutic strategies that use in vivo gene editing.
VIVO consists of two steps (Fig. 1a ). In an initial in vitro 'discovery' step, a superset of potential off-target cleavage sites for a nuclease is identified using circularization for in vitro reporting of cleavage effects by sequencing (CIRCLE-seq) 8 . This method is highly sensitive, avoids potential confounding effects associated with cell-based assays 8 and can successfully identify supersets of sites that include bona fide off-targets in cultured human cells 8 . In a second in vivo 'confirmation' step, sites identified by CIRCLE-seq are examined for indel mutations in target tissues that have been treated with the nuclease.
To test VIVO, we designed a Streptococcus pyogenes Cas9 (hereafter, Cas9) guide RNA (gRNA) targeted to the mouse Pcsk9 gene that we expected would have a high likelihood of inducing multiple off-target mutations in the mouse genome (Extended Data Fig. 1a , Extended Data Table 1 and Methods). To deliver this 'promiscuous' gRNA (gP) and Cas9 to mouse livers in vivo, we infected cohorts of mice with an adenoviral vector that encodes these components or with a negative control vector that encodes GFP and Cas9. Adenoviral vectors have a known biodistribution, which includes efficient delivery to the liver (Extended Data Fig. 2 ). Two strains of mice were infected: a wild-type C57BL/6N strain (hereafter, wild-type mice) and littermates that contain a single copy of a human PCSK9 open reading frame knocked into the Rosa26 locus (hereafter, knock-in mice; A.C. et al., manuscript submitted; Extended Data Fig. 3 and Methods). gP-Cas9 induced stable and efficient mutation of the on-target Pcsk9 site and reductions in Pcsk9 protein levels in plasma, in both wild-type and knock-in mice (Extended Data Fig. 1b, c) .
Having established the efficacy of gP-Cas9 for on-target Pcsk9 modification in vivo, we conducted the first screening step of VIVO by performing CIRCLE-seq with gP-Cas9 on liver genomic DNA from wild-type and knock-in mice ( Fig. 1a and Methods). We identified many off-target cleavage sites in vitro: 3,107 and 2,663 sites with wildtype and knock-in mice genomes, respectively (Extended Data Fig. 4 and Supplementary Table 1 ). These sites represent only a small percentage of all sites in the genome that have seven or fewer mismatches relative to the on-target site (Extended Data Fig. 5 ). There were 2,368 sites that were identified in both mouse genomes and that showed strong concordance (r 2 = 0.902) in their CIRCLE-seq read counts (Extended Data Fig. 4 ), which semi-quantitatively reflect cleavage efficiency 8 . Sites identified in only one or the other genome generally had among the lowest CIRCLE-seq read counts (Extended Data Fig. 4 ). This is consistent with the possibility that these sites may or may not be detected by chance alone because they lie at the assay limit of detection, as has previously been observed with analogous experiments in human cells in culture 8 . Single nucleotide polymorphisms or indels might also have a role in accounting for a very small subset of these sites (Extended Data Table 2 ). The 20 sites with the highest CIRCLE-seq read counts all had 3 or fewer mismatches in the spacer sequence (Extended Data Fig. 4 and Supplementary Table 1 ). Many off-target sites contained protospacer adjacent motif (PAM) mismatches, with NAG as the most prevalent (Extended Data Fig. 4 and Supplementary Table 1 )-probably because gP has an unusually high relative number of closely matched sites in the mouse genome with a NAG PAM (Extended Data Table 3 ), a known alternative PAM for Cas9 8,9 . To perform the second step of VIVO, we assessed whether the off-target cleavage sites of gP-Cas9 identified by CIRCLE-seq showed evidence of indels in vivo in the livers of wild-type and knock-in mice treated with gP-Cas9 and control GFP-Cas9 adenoviral vectors. Because of the very large number of sites identified by CIRCLE-seq, we performed targeted amplicon sequencing using liver genomic DNA from mice euthanized on day four and on week three after infection on only the following subsets of sites: the Pcsk9 on-target site, 11 'class I' sites with the highest CIRCLE-seq read counts (containing 1-3 mismatches relative to the on-target site), 17 'class II' sites with moderate CIRCLE-seq read counts (containing 2-4 mismatches) and 17 'class III' sites with lower CIRCLE-seq read counts (containing 1-6 mismatches) ( Fig. 1b and Extended Data Fig. 4 ). The Pcsk9 ontarget site was efficiently mutagenized and remained stably mutated in both wild-type and knock-in mice (mean indel frequencies ranging from about 23 to 30%) ( Fig. 1b and Supplementary Table 2 ). Of the Letter reSeArCH 45 sites we examined, 19 showed significant evidence of indels (mean frequencies ranging from 41.9% to 0.13%) in wild-type and knock-in mouse livers at day four and at week three after infection ( Fig. 1b and Supplementary Table 2 ). Notably, higher CIRCLE-seq read counts generally correlated well with the likelihood of finding indels in vivo: 11 of the 11 class I off-target sites, 5 of the 17 class II sites and 3 of the 17 class III sites contained indels ( Fig. 1b ). All 19 of these sites had 3 or fewer mismatches relative to the on-target site, with the majority of the sites located within gene-coding sequences ( Fig. 1b ). Three additional sites-including two sites each containing three mismatches in the spacer and one mismatch in the PAM-showed significant evidence of indel mutations at the four-day time point, but which was no longer significant by three weeks (Supplementary Table 2 ); the mutation frequencies observed at these sites were around 0.13%, which is close to the limit of detection (0.1%) for next-generation sequencing 10 . These data show that Cas9 with a promiscuous gRNA can generate stable, and sometimes high-frequency, off-target mutations in vivo and that VIVO can identify such mutations even with frequencies as low as 0.13%.
Because potential therapeutic applications would not use a promiscuous gRNA with so many closely matched genomic sites, we sought to assess the in vivo off-target profiles of Cas9 gRNAs designed to be more orthogonal to the mouse genome. We constructed two additional gRNAs (abbreviated as gM 11 and gMH) that are targeted to mouse Pcsk9 (Extended Data Fig. 6a ) but have relatively few closely matched sites in the C57BL6/N mouse genome (Extended Data Table 1 ). gMH also targets a site (with one mismatch) in the human PCSK9 open reading frame, which is integrated in the knock-in mouse genome (Extended Data Fig. 6a ). Delivery of gM-Cas9 and gMH-Cas9 by adenoviral vectors induced expected genetic alterations in the mouse Pcsk9 gene and human PCSK9 transgene as well as corresponding decreases in the levels of Pcsk9 and PCSK9 in plasma (Extended Data Fig. 6b , c).
We conducted the first in vitro CIRCLE-seq step of VIVO with gM-Cas9 and gMH-Cas9 on wild-type and knock-in mouse genomic DNA. The on-target mouse Pcsk9 was identified in all four experiments and the human PCSK9 transgene site only in the experiment with gMH on knock-in mouse DNA (Fig. 2 ). We identified fewer off-target sites with gM-Cas9 and gMH-Cas9 ( Fig. 2 and Supplementary Tables 3, 4) than we had with gP-Cas9. When using gM, we found 182 off-target sites: 129 with wild-type mouse DNA, 145 with knock-in mouse DNA and 92 sites that were common to both. When using gMH, we found 529 off-target sites: 333 with wild-type mouse DNA, 394 with knock-in mouse DNA and 198 sites that were common to both. All but 2 of the 711 off-target sites that were identified with these gRNAs had 3 or more mismatches, consistent with the higher orthogonality of these gRNAs relative to the mouse genome. For both gRNAs, there were good concordances in CIRCLE-seq read counts between the wild-type and knock-in mice when considering all off-target sites that were identified (r 2 = 0.747 and 0.841 for gM and gMH, respectively) ( Fig. 2 ). As when using gP, sites that were found in only one mouse genome generally had low CIRCLE-seq read counts (Fig. 2) , and analysis of gM CIRCLE-seq and targeted amplicon sequencing data suggests that these differences are not due to single nucleotide polymorphisms (Extended Data Table 2 and Supplementary Table 5 ). . Each locus was assayed in n = 3 biologically independent wild-type (WT) and knock-in (KI) mice (labelled as 1, 2 and 3) using genomic DNA isolated from the liver of mice treated with experimental adenoviral vector that encodes gP-Cas9 (gRNA +) or control adenoviral vector that encodes GFP-Cas9 (gRNA −). Mismatches relative to the on-target site are shown with coloured boxes. CIRCLE-seq read-count numbers for each site are shown. Sites that showed a significant difference between the experimental (gRNA +) and control (gRNA −) samples are outlined with orange boxes and labelled by genomic locus, with coding regions shown in purple text. P values and significance were obtained by fitting a negative binomial generalized linear model (for source data and P values, see Supplementary Table 2 ). 
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We conducted the second in vivo step of VIVO for gM and gMH by performing targeted amplicon sequencing of sites found by CIRCLEseq in liver genomic DNA of adenovirus-treated wild-type and knock-in mice. For gM, we comprehensively examined 181 of the 182 off-target CIRCLE-seq cleavage sites (one site could be amplified but not sequenced; see Methods) and the on-target site from liver DNA collected at day 4 or week 3 after adenovirus infection. Notably, only the gM on-target site showed significant evidence of indels (ranging from 12.6% to 18.5%) ( Fig. 3 and Supplementary Table 6 ); no significant off-target indels were identified at any of the 181 off-target sites in either mouse at either time point. Because CIRCLE-seq identified a large number of potential off-target sites (529 in total) when using gMH, we examined the on-target site and a subset of the off-target sites (comprising 69 sites) that had the highest CIRCLE-seq read counts (and up to 6 mismatches). These 69 sites encompassed all but 1 of the CIRCLE-seq sites that had up to 3 mismatches (1 site could be amplified but not sequenced; see Methods) and the human PCSK9 transgene site (with 1 mismatch) ( Fig. 2 ). This choice was guided by our finding that none of the 19 stable in vivo off-target sites we found for gP-Cas9 had 4 or more mismatches relative to the on-target site ( Fig. 1b ). Among the 69 sites, we found significant indel mutations at only the on-target mouse gMH site (27.4-43.6% indels) and the human PCSK9 transgene site bearing one mismatch (20.4-21.7% indels) (Extended Data Fig. 7 and Supplementary Table 7 ).
To further exclude the possibility that CIRCLE-seq missed any bona fide off-target sites, we also performed targeted amplicon sequencing Indel frequencies determined by targeted amplicon sequencing for the gM-Cas9 on-target site (black square) and 181 off-target sites identified by CIRCLE-seq. Each condition shown was assayed in n = 3 biologically independent mice (labelled 1, 2 and 3) using genomic DNA isolated from the liver of mice treated with experimental adenoviral vector that encodes gM-Cas9 (gRNA +) or control adenoviral vector that encodes GFP-Cas9 (gRNA −). Data are presented as in Fig. 1b . The single site (the on-target site) that was significantly different between the experimental (gRNA +) and control (gRNA -) samples is highlighted with orange boxes. Additional closely matched sites in the mouse genome (not identified from the CIRCLE-seq experiments) examined for indel mutations are boxed in red. For source data and P values (negative binomial), see Supplementary Table 6 . read count   1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 2 3   KI  4 days 3 weeks 4 days 3 weeks   WT   -+  -+  -+  -+   Pcsk9   Gene   1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 2 3  1 Letter reSeArCH of the most closely matched sites in the mouse C57BL/6N genome (containing up to three mismatches in the spacer) that were not identified in our CIRCLE-seq experiments (four sites for gM and ten sites for gMH) (Extended Data Table 1 ). Three of the gM sites could not be individually selectively amplified and so these were assessed together as a pool (Methods). We did not observe significant indels at any of these sites in all treated mice at both time points ( Fig. 3 , Extended Data Fig. 7 and Supplementary Tables 6, 7) . To our knowledge, our report provides the first demonstration that CRISPR-Cas nucleases can robustly induce off-target mutations in vivo. Previous in vivo studies have reported no or very few off-target mutations, but used the cell-based 'genome-wide unbiased identification of double-strand breaks enabled by sequencing' (GUIDE-seq) method [12] [13] [14] or other in silico approaches that have not been validated to effectively identify these sites in vivo (see Supplementary  Discussion) . By contrast, VIVO enabled the robust and sensitive identification of off-target sites in vivo, even those with mutation frequencies as low as about 0.13%. The high sensitivity of CIRCLEseq is most probably what enabled the identification of a superset of all potential off-target sites, including those actually mutated in vivo (Supplementary Discussion). The detection limit of VIVO-as with all existing methods-is bounded by the current error rate of next-generation sequencing for indels (approximately 0.1%). In addition, we did not attempt to detect large-scale chromosomal rearrangements (translocations, inversions or large deletions) but we expect the frequencies of such alterations to be no higher than that of any off-target indels. Other methods 15 might be used in future studies to test for these alterations.
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CIRCLE-seq
VIVO defines a pathway for assessing the in vivo genome-wide specificities of CRISPR-Cas nucleases. Our work suggests that gRNAs should be designed to have the lowest possible number of closely matched genomic sites (with three or fewer mismatches), which can be done using existing in silico tools 16 . Such gRNAs can be assessed in step 1 of VIVO to identify those that have a reasonable number (<100-200) of in vitro off-target cleavage sites and then these sites can be comprehensively examined for indels in vivo using targeted amplicon sequencing in step 2 of VIVO. We also recommend examination of any other closely matched genomic sites (fewer than four mismatches) that are not identified by CIRCLE-seq. Persistent off-target mutations might be further reduced using various strategies for improving the genome-wide specificities of CRISPR-Cas nucleases (Supplementary Discussion).
We believe VIVO sets an important standard for defining in vivo off-target effects of gene-editing nucleases. The approach should be generalizable to non-CRISPR gene-editing nucleases, to non-mammalian organisms and to other delivery methods (Supplementary Discussion). VIVO should also be useful for characterizing the in vivo specificities of engineered CRISPR-Cas9 variants and other CRISPR-Cas orthologues (Supplementary Discussion) and for assessing the effectiveness of methods for reducing the off-target effects of these nucleases. We expect our findings will advance research and methods that will further spur the clinical translation of in vivo genome-editing therapeutic strategies.
Note added in proof: a recent study 17 that investigated large-scale chromosome alterations resulting from CRISPR-Cas9 editing found that the frequencies of these alterations were indeed no higher than those of the off-target indels we report here.
Online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/s41586-018-0500-9.
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MEthodS gRNA design. gP was identified by searching for an on-target sequence within mouse Pcsk9 (ENSMUSG000044254) exons one to three that showed a high number of closely matched sites (two or fewer mismatches to the on-target site) in the mouse genome. gMH was designed by searching for a gRNA that can cleave both mouse Pcsk9 and human PCSK9, and that showed a perfect alignment to mouse Pcsk9 and up to two nucleotides mismatch to human PCSK9 (ENSG00000169174) at least eight nucleotides distal from the PAM. For both gRNA designs, AstraZeneca proprietary software was used as an in silico tool, which was developed based on the codebase of the Wellcome Trust Sanger Institute (WGE: http://www.sanger. ac.uk/htgt/wge/) 18 with the addition of the NAG PAM motif and NGG in the alignments for potential off-targets 9 . GRCm38/mm10 and GRCh38/hg38 genomes were used as reference for alignments. The gM targeted to mouse Pcsk9 has previously been described 11 . Adenoviral constructs. Adenoviruses that express Cas9 and gRNAs (Ad-Cas9-gM, Ad-Cas9-gMH and Ad-Cas9-gP) were generated by Vector Biolabs (Malvern). Cas9 and gRNAs were expressed from chicken β-actin hybrid (CBh) and U6 promoters, respectively, in a replication-deficient adenoviral-serotype 5 (dE1/E3) backbone. A negative control adenovirus (Ad-Cas9-GFP) that expresses Cas9 and GFP from the CBh and CMV promoters, respectively, but no gRNA was also generated. Animal studies. All animal experiments were approved by the AstraZeneca internal committee for animal studies as well as the Gothenburg Ethics Committee for Experimental Animals (license number: 162-2015+), compliant with EU directives on the protection of animals used for scientific purposes.
C57BL/6N mice (Charles River) were individually housed in a temperature (21 ± 2 °C) and humidity (55 ± 15%) controlled room with a 12:12-h light:dark cycle. R3 diet (Lactamin AB) and tap water were provided ad libitum. Cage bedding and enrichments include spen chips, shredded paper, gnaw sticks and a plastic house.
A humanized hypercholesterolaemia mouse model was generated by liverspecific overexpression of human PCSK9 in C57BL/6N mice (A.C. et al., manuscript submitted). In brief, the knock-in mouse was generated by cloning the human PCSK9 open reading frame downstream of the mouse albumin promoter from albumin-Cre mice, in a vector designed to target the mouse Rosa26. Founder C57BL/6N hPCSK9 heterozygous males were crossed with C57BL/6N females to generate experimental animals, which are littermates with two genotypes: C57BL/6N hPCSK9KI +/− (referred to as knock-in) and wild-type C57BL/6N hPCSK9KI −/− (referred to as wild-type) (Extended Data Fig. 3 ).
For in vivo Pcsk9 gene editing, nine-to eleven-week-old male mice received a tail vein injection with a dose of 1 × 10 9 infection units (IFU) of adenovirus (Ad-Cas9-gM, Ad-Cas9-gMH, Ad-Cas9-gP or Ad-Cas9-GFP) in 200 μl diluted with phosphate-buffered saline. Peripheral blood was sampled before virus administration (baseline), a week after virus administration and at termination (four days or three weeks after virus administration). Animals were euthanized by cardiac puncture under isoflurane anaesthesia at the experimental endpoint. The organsincluding liver, spleen, lungs, kidney, muscle, brain and testes-were dissected, snap-frozen in liquid nitrogen and stored at −80 °C until further analyses.
Ten milligrams of frozen liver tissue was lysed to obtain 30-50 μg genomic DNA using the Gentra Puregene Tissue kit (Qiagen). In vivo gene-editing efficiency was evaluated using Surveyor mismatch cleavage assay (Integrated DNA Technologies, BVBA) (using primers: for gP, GAGGCCGAAACCTGATCCTT and CTTAGAGACCACCAGACGGC; for gM, GGAGGACACGTTTTCTGCAT and CTGCTGCTGTTGCTGCTAC; for gMH mouse locus, GACTTTGTGA AGGCTGGGGA and TGCATGGAGCAATGCAGAGA; for gMH human transgene, TAGCCTTGCGTTCCGAGGAG and CATTCTCGAAGTCGGTGACCA; with amplicon sizes 619, 415, 349, 495 base pairs, respectively) and targeted deep sequencing (primers listed in Supplementary Tables 2, 6 and 7) .
Animals were randomized based on their weights measured before the experiments. The investigators were blinded to group allocation during data collection and analysis. No sample size calculation was performed. Sample size was determined to generate triple independent samples for comparisons between groups sufficient to perform statistical tests.
Assessment of human PCSK9 and/or mouse Pcsk9 protein levels in plasma.
Peripheral blood was collected in EDTA-coated capillary tubes from vena saphena during the course of the study and by cardiac puncture at the time of termination. Samples were kept on ice for up to 2 h before extraction of plasma by centrifugation at 10,000 rpm for 20 min at 4 °C. Plasma was stored at −80 °C until the samples were analysed. Levels of human PCSK9 and mouse Pcsk9 in plasma were determined with a standard ELISA kit (DPC900 and MPC900; R&D Systems) according to the manufacturer's instructions. Prior to the assay, plasma samples were diluted 1:800 and 1:1,000 for human PCSK9 and mouse Pcsk9, respectively. Reference genome for CIRCLE-seq, CRISPResso and Cas-OFFinder. Build 38 of the C57BL/6NJ genome, sequenced by the Sanger Mouse Genomes Project (http://csbio.unc.edu/CCstatus/index.py?run=PseudoOld), was used as the reference genome for the experiments of this report. The human PCSK9 gene DNA sequence was inserted into the mouse genome as an extra chromosome in the reference and was named as 'chrPCSK9KI' . CIRCLE-seq. CIRCLE-seq was performed experimentally as previously described 8 . Data were processed using v.1.1 of the CIRCLE-Seq analysis pipeline 8 (https://github.com/tsailabSJ/circleseq) with parameters: 'window_size: 3; mapq_threshold: 50; start_threshold: 1; gap_threshold: 3; mismatch_threshold: 7; merged_analysis: False, variant_analysis: True' . The gP off-target sites were adjusted for mapping artefacts in highly repetitive regions by consolidating contiguous sites whose mapping positions differed by 5 base pairs or less. The off-target sequences reported for these consolidated sites were obtained by performing the local alignment used in the CIRCLE-seq pipeline. Targeted amplicon deep sequencing of off-targets. Genomic DNA from liver tissue of adenovirus-injected mice was extracted at day 4 and at week 3 post-treatment for indel analysis. As detailed in the text, we validated off-targets identified by CIRCLE-seq by selecting sites with read counts above 50% of the on-target and a variety of lower-ranked sites (containing up to 6 mismatches relative to the on-target) for targeted deep sequencing. In addition, we ruled out the possibility that CIRCLE-seq was missing potential off-target sites identified using in silico tools by sequencing all sites containing up to 3 mismatches, identified by Cas-OFFinder 16 for gM and gMH. All sites we analysed were amplified from 150 ng of input genomic DNA (approximately 5 × 10 4 genomes) with Phusion Hot Start Flex DNA polymerase (New England Biolabs). PCR products were purified using magnetic beads made as previously described 19 , quantified using a QuantiFlor dsDNA System kit (Promega), normalized to 10 ng/μl per amplicon and pooled. Pooled samples were end-repaired and A-tailed using an End Prep Enzyme Mix and reaction buffer from NEBNext Ultra II DNA Library Prep Kit for Illumina, and ligated to Illumina TruSeq adapters using a ligation master mix and ligation enhancer from the same kit. Library samples were then purified with magnetic beads made as previously described 19 , size-selected using PEG/NaCl SPRI solution (KAPA Biosystems), quantified using droplet digital PCR (BioRad) and loaded onto an Illumina MiSeq for deep sequencing. To analyse amplicon sequencing of potential on-and off-targets, we used CRISPResso software 20 v1.0.11 (https://github.com/ lucapinello/crispresso) with the following parameters: '-q 30 --ignore_substitutions --hide_mutations_outside_window_NHEJ' .
For each of the 45 gP off-target sites we examined, we obtained 10,000 or more sequencing reads in at least 2 samples for treated and control samples at all time points (Supplementary Table 2 ). One potential gM off-target site (chr15:98037617-98037640) and one potential gMH off-target site (chr15:4878177-4878200) were amplified but could not be successfully sequenced. The problematic gM site was amplified with two different sets of primers and both amplicons failed to sequence. The gMH site is in a highly repetitive area with low complexity and we were unable to differentiate this site from other sites in the genome; therefore, the site was removed from analysis. For all of the gM off-target sites we were able to sequence, we obtained 10,000 or more sequencing reads in at least 2 samples for treated and control samples at all time points (Supplementary Table 6 ). For all but 1 of the gMH off-target sites we were able to sequence, we obtained 10,000 or more sequencing reads in at least 2 samples for treated and control samples at all time points (Supplementary Table 7 ). One of the gMH off-target sites we sequenced (chr17:33501685-33501708) did not reach the 10,000 read threshold for any samples or time points but read counts ranged from 2,509 to 9,149. We were unable to individually and selectively amplify three sites that were identified in silico as being highly similar to the gM on-target site but that were not identified by CIRCLE-seq, owing to their sequence similarities: these sites were chr14:25878231-25878254, chr14:26018001-26018024 and chr14:26157615-26157638. Therefore, for these three sites the read counts were pooled into one amplicon that encompasses all locations and that is labelled as 'chr14:pooled' in Supplementary Table 6 . Targeted amplicon deep sequencing of wild-type and knock-in untreated mice. Genomic DNA from liver tissue of untreated mice-the same mice upon which CIRCLE-seq was performed-was amplified at sites that contained no reads in either the knock-in or wild-type CIRCLE-seq for gM and deep sequenced to look for single nucleotide polymorphisms (Supplementary Table 5 ). Primers used are the same as in Supplementary Table 6 . Sites were analysed with CRISPRessoPooled with the following parameters: '--cleavage_offset -7 --window_around_sgrna 13' , to perform a focused variant analysis in the spacer. Cas-OFFinder. Identification of potential off-targets by Cas-OFFinder 16 (https:// github.com/snugel/cas-offinder, v. 2.4) was done using the off-line version, allowing up to 7 mismatches and non-canonical PAMs. We then restricted the output to the sites with at most 6 mismatches in the spacer and at most 1 mismatch in the PAM. Non-reference genetic variation. samtools (mpileup and bcftools, v.1.3.1 21 ) was used to discover non-reference genetic variation at the off-target sites identified by CIRCLE-seq. Positions with a genotype-quality score greater than 5 and depth
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Extended Data Fig. 1 | gP-Cas9 efficiently mutates the mouse Pcsk9 gene and reduces levels of Pcsk9 protein in plasma in vivo. a, gP was designed to target a sequence within exon 1 of the mouse Pcsk9 gene that has many closely related genomic sites (that is, those with 1-3 mismatches relative to the on-target site; Extended Data Table 1 ). Blue bars indicate exons for the mouse genomic region. b, Surveyor assay and next-generation DNA sequencing data demonstrate efficient in vivo modification of the on-target mouse Pcsk9 gene site in mouse liver by gP-Cas9. Assays were performed on day 4 and on week 3 after the administration of adenoviral vectors that encode gP-Cas9 (gP) or negative control GFP-Cas9 (GFP). For each time point, the assays used genomic DNA isolated from livers of n = 3 biologically independent wild-type C57BL/6N (WT) mice or C57BL/6N-derived mice containing a single copy of the human PCSK9 open reading frame under albumin promoter, knocked into the Rosa26 locus (KI). Asterisks indicate the cleaved PCR products expected after treatment with Surveyor nuclease. Percentages show the frequencies of indel mutations determined by targeted amplicon sequencing using next-generation sequencing; these are the same values shown for the on-target site in Fig. 1b . Lines divide lanes taken from different locations on the same gel. For source data for Surveyor assays and targeted amplicon sequencing, see Supplementary  Fig. 1 and Supplementary Table 2 , respectively. c, Mouse Pcsk9 protein levels in plasma measured in n = 3 biologically independent wild-type and knock-in mice and human PCSK9 protein levels in plasma measured in n = 3 biologically independent knock-in mice, after nuclease treatment. Protein levels were assessed on day 4, 7 and week 3 after administration of gP or control GFP adenoviral vectors and normalized to baseline levels. Significant differences between experimental and control groups were determined using two-way ANOVA and Sidak's two-sided adjusted multiple comparisons test; **P < 0.01, ***P < 0.001, ****P < 0.0001. See Source Data for Extended Data Fig. 4b for exact adjusted P values. All values are presented as group means, and error bars represent standard error of the mean. The enhanced reduction of levels of Pcsk9 in plasma relative to the frequency of observed Pcsk9 genetic alteration is consistent with previously published studies (Supplementary Discussion). the PAM sequence for the sites is in bold and the spacer sequence is underlined. b, Surveyor assay and next-generation DNA sequencing data demonstrate efficient in vivo modification of the on-target endogenous mouse Pcsk9 site and human PCSK9 transgene in mouse liver. Assays were performed at day 4 and at week 3 after administration of adenoviral vectors that encode gM and Cas9 (gM), gMH and Cas9 (gMH) or GFP and Cas9 (GFP) using genomic DNA isolated from livers of n = 3 biologically independent wild-type and knock-in mice. Asterisks indicate the cleaved PCR products expected following treatment with Surveyor nuclease. Percentages show the frequencies of indel mutations determined by targeted amplicon sequencing using next-generation sequencing; these are the same values shown for the on-target sites in Fig. 3 and Extended Data Fig. 7 . Lines divide lanes taken from different locations on the same gel. For source data for Surveyor assays, see Supplementary Fig. 1 . For source data for targeted amplicon sequencing, see Supplementary Tables 6 and  7 for gM and gMH, respectively. b, Mouse Pcsk9 protein levels measured in plasma in n = 3 biologically independent wild-type and knock-in mice, and human PCSK9 protein levels measured in plasma in n = 3 biologically independent knock-in mice after CRISPR-Cas nuclease treatment. Protein levels in plasma were assessed at day 4, 7 and week 3 after the administration of gM, gMH or control GFP adenoviral vectors and normalized to baseline levels at each time point. Significant differences between groups were determined using two-way ANOVA and Dunnett's two-sided adjusted multiple comparisons test; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. See Source Data for exact adjusted P values. Values are presented as group means, error bars represent standard errors of the mean.
Extended data table 2 | off-target sites identified by CIRCLE-seq for gP, gM and gMh that exhibit single nucleotide polymorphisms or indels based on CIRCLE-seq data Mismatches relative to the on-target site are shown as lower-case letters. Single nucleotide polymorphisms or indels that differ from the C57BL/6N mouse strain are shown as red-coloured letters. Targeted amplicon sequencing of sites for gM (first row) was performed with the same genomic DNA from wild-type and knock-in mice used for CIRCLE-seq experiments (data in Supplementary Table 7 ). N.D. = not done. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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Data collection
For guide RNA design we used AstraZeneca proprietary software as an in silico tool, which was developed based on Wellcome Trust Sanger Institute`s codebase (WGE: http://www.sanger.ac.uk/htgt/wge/) with the addition of the NAG PAM motif as well as NGG in the alignments for potential off-targets. In silico mismatch data was obtained with Cas Offinder software (https://github.com/snugel/casoffinder).
Data analysis
Data visualization and statistical analyses for plasma protein measurements were performed using GraphPad Prism 7.02. For circle-seq (data analyzed with CIRCLE-seq software: https://github.com/tsailabSJ/circleseq) and amplicon sequencing data (analyzed with CRISPResso: https://github.com/lucapinello/CRISPResso) was visualized and statistically tested with R, version 3.4.3.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information. Figures 1 and 6 available in Supplementary Figure 1 .
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Sample size
No sample size calculation was performed. Sample size was determined as generation of triple independent samples for comparisons between groups that is sufficient to perform statistical tests.
Data exclusions No data were excluded.
Replication
The experimental findings can be reliably reproducible. Some experiments producing the key data were repeated by different co-authors.
Randomization Animals were randomized based on their weights measured prior to the experiments.
Blinding
The investigators were blinded to group allocation during data collection and analysis, except Surveyor assays -due to the need of visual organization of the groups to generate easily readable images.
Reporting for specific materials, systems and methods AstraZeneca can share the animal model under a signed material transport agreement after that article is accepted for publication.
